Related Experiment Video
Updated: Jul 22, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
A regulatory model for clinical laboratories: an empirical evaluation
1Graduate School of Public Health, College of Health and Human Services, San Diego State University, CA 92182-0405.
This study evaluates how well regulatory requirements for U.S. clinical laboratories translate into actual performance. It finds that compliance with regulations explains only a small portion of performance variation, suggesting that other factors are important. The study uses regression models to show that laboratory characteristics vary in their impact on performance across different specialties. These findings indicate that the current regulatory model may not be sufficient to ensure the highest performance levels. The authors propose that regulatory frameworks should be more flexible and include additional factors to better align with real-world outcomes.
Area of Science:
- Clinical laboratory regulation
- Healthcare quality assurance
- Medical accreditation systems
Background:
Current understanding of clinical laboratory regulation includes a focus on compliance with mandated standards for personnel, quality control, and analytical proficiency. Prior research has shown that these standards are intended to ensure consistent and accurate diagnostic results. However, it remains unclear how well these regulations translate into actual performance outcomes. No prior work had resolved whether compliance alone is sufficient to guarantee high proficiency. This gap motivated a closer look at the relationship between regulatory adherence and real-world performance. Existing studies have not fully explored the variability of performance across different laboratory specialties. That uncertainty drove the need to evaluate how regulatory models function in practice. This paper contributes by analyzing compliance data alongside performance metrics in a diverse sample of U.S. clinical laboratories. The findings offer insights into the limitations of current regulatory frameworks.
Purpose Of The Study:
The aim of this study is to evaluate the relationship between regulatory compliance and analytical proficiency in U.S. clinical laboratories. It addresses the specific problem of whether regulatory mandates effectively translate into high performance. The motivation stems from observed variability in laboratory performance despite adherence to the same standards. This study seeks to identify which laboratory characteristics are most predictive of proficiency. It also aims to assess the extent to which regulatory models capture the factors influencing performance. The study is designed to inform potential improvements to the regulatory system. By analyzing a cross-section of laboratories, it provides a broader perspective on compliance and performance. The results may help refine current regulatory approaches to better align with actual outcomes.
Main Methods:
This study uses an empirical evaluation approach to analyze compliance and performance data from a sample of U.S. clinical laboratories. It collects data on regulatory compliance, laboratory characteristics, and analytical proficiency test results. Regression models are employed to assess the relationship between these variables. The analysis includes a cross-sectional sample to capture variability across different specialties. Data sources include regulatory reports and proficiency testing records. Statistical methods are used to quantify the proportion of performance variation explained by compliance factors. The study compares laboratory characteristics across specialties to identify patterns. The findings are presented as regression models that highlight key predictors of performance.
Main Results:
The strongest finding is that compliance with regulatory requirements explains only 12% to 35% of the variation in analytical performance. This suggests that factors beyond regulatory compliance influence proficiency. Some laboratory characteristics are more predictive of performance than others. These characteristics differ depending on the laboratory specialty. For example, certain variables are more strongly associated with performance in pathology labs than in clinical chemistry labs. The results indicate that the current regulatory model may not ensure the highest performance levels. The study identifies gaps in the regulatory framework that fail to account for important performance drivers. These findings suggest that additional factors, not currently specified in regulations, are significant. The data highlight the need for a more nuanced regulatory approach.
Conclusions:
The authors propose that the current regulatory model may not fully ensure high analytical performance. They suggest that factors outside of regulatory requirements are important in determining proficiency. The findings indicate that laboratory characteristics vary in their predictive value across specialties. This implies that a one-size-fits-all regulatory approach may be insufficient. The study highlights the limitations of existing regulatory frameworks in capturing all performance drivers. It suggests that additional factors, not included in current regulations, should be considered. The authors emphasize the need for a more flexible and adaptive regulatory system. These conclusions are based on the observed variability in performance and the limited explanatory power of regulatory compliance alone.
Frequently Asked Questions
The study finds that regulatory compliance explains only 12% to 35% of the variation in analytical performance, suggesting factors beyond compliance influence proficiency.
Analytical proficiency is defined as performance on standardized tests that measure the accuracy and consistency of laboratory results.
The regulatory model is considered insufficient because it explains only a portion of performance variation, indicating other factors are important.
Laboratory characteristics, such as personnel and quality systems, vary in their predictive value across specialties and influence performance.
The regression models show that compliance alone does not fully explain performance, highlighting the need for additional regulatory considerations.
The findings suggest that regulatory frameworks should be more flexible and include factors beyond current compliance requirements.
Related Concept Videos
Enzyme-Linked Immunosorbent Assay
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
Data Validation
Key parameters for method validation include:
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
In Vitro Drug Dissolution: Compendial Testing Models I
Clinically Relevant Drug Product Specifications: Methods of Establishment
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

